Skip to content
Application 062640
- Type
- ANDA
- Sponsor
- ACS DOBFAR
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | CEFTAZIDIME | CEFTAZIDIME | INJECTABLE;INJECTION | 500MG/VIAL | No | No |
| 002 | CEFTAZIDIME | CEFTAZIDIME | INJECTABLE;INJECTION | 1GM/VIAL | No | No |
| 003 | CEFTAZIDIME | CEFTAZIDIME | INJECTABLE;INJECTION | 2GM/VIAL | No | No |
| 004 | CEFTAZIDIME | CEFTAZIDIME | INJECTABLE;INJECTION | 6GM/VIAL | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 0781-3177 | Ceftazidime | Ceftazidime | Sandoz Inc | ANDA | Current |
| 0781-3178 | Ceftazidime | Ceftazidime | Sandoz Inc | ANDA | Current |
| 0781-3179 | Ceftazidime | Ceftazidime | Sandoz Inc | ANDA | Current |
| 25021-127 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-127 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-127 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-127 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-127 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-127 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-128 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-128 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-128 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-128 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-128 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-128 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-128 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-129 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-129 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-129 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-129 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-129 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 25021-129 | Ceftazidime | ceftazidime | Sagent Pharmaceuticals | ANDA | Current |
| 44567-235 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-235 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-235 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-235 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-235 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-236 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-236 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-236 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-236 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-236 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-237 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-237 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-237 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-237 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |
| 44567-237 | Ceftazidime | Ceftazidime | WG Critical Care, LLC | ANDA | Current |